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There were 87 participants from 22
different countries at this Symposium. The
various aspects on trophoblastic tumours
discussed included pathology, genetics, epi-
demiology, immunology, endocrinology,
monitoring and follow-up services, prognostic
factors and therapy.
PATHOLOGY, GEYNETICS AND EPIDEMIOLOGY
Professor W. W. Park (Dundee) discussed
some of the pathological problems that per-
sist with gestational trophoblastic tumours.
One important reason why some ofthe patho-
logical questions have remained unanswered
for many years is that the incidence of these
tumours is highest in the tropics, where the
facilities for pathological research and follow-
up are limited. In most, if not all cases of
choriocarcinoma, there has been a preceding
normal or abnormal pregnancy, though, in
some patients, conception has not been
followed by an identified pregnancy. It re-
mains a possibility that during embryogenesis
some cells differentiate to malignant tropho-
blast without the differentiation of other
embryonic tissues; the so called "ab initio"
choriocarcinoma.
Widespread dissemination of choriocarcin-
oma with apparent healing of the original
primary in the uterus, leaving a scar or
necrosis, probably occurs. There is now good
evidence also that an abnormal trophoblast
can persist following a molar pregnancy for
many years, sometimes with an intervening
normal pregnancy, before the abnormal
trophoblast grows sufficiently to become
clinially apparent. The rarity of involvement
of the foetus by post-full-term choriocarcin-
oma suggests that the foetus is able to destroy
the malignant isograft, since it is likely that
at least some choriocarcinoma cells would
enter the foetal circulation during the preg-
nancy.
Dr C. W. Elston (Nottingham) discussed
the geographical distribution that has been
recorded for hydatidiform moles, varying
from 1/200 deliveries in the third world to
1/2000 deliveries in the United States. To
avoid the bias of statistics taken purely from
hospital confinements, he conducted a survey
covering 87,350 deliveries in the Nottingham
area between 1970 and 1978. There were 57
hydatidiform moles: an incidence of 1/1530
deliveries. Fifty of the moles showed com-
plete hydropic change. The mean age of the
patients was 25. Ofthe 48 that were available
for follow-up for more than 1 year, one had
required a hysterectomy and 3 had required
chemotherapy, providing an overall com-
plication rate of8%
Professor D. Attygalle (Sri Lanka) pre-
sented the results of a 10-year survey be-
tween 1969 and 1978 in Colombo, where they
had seen 288 histologically confirmed gesta-
tional trophoblastic tumours during this
period. The histological classification of these
were hydatidiform mole in 233 (87.8%),
invasive mole in 13 (4-5%) and choriocarcin-
oma in 22 (7-6%) All these tumours occurred
in the Sinhalese, who form 75%O of the popu-
lation. Hydatidiform moles occurred with
diminishing frequency withincreasingnumber
ofpregnancies, and was commoner inyounger
patients (20-29 years). Choriocarcinoma was
a sequel in about 10% of the patients with
hydatidiform moles. The choriocarcinoma
patients who were treated by hysterectomy
and methotrexate, showed a survival rate
of50% at 3-4 years.TROPHOBLASTIC TUMOURS
Dr S. D. Lawler (London) discussed some
genetic aspects of trophoblastic tumours.
Clearly these tumours are unique, in that the
tissue involved is always genetically foreign
to the host. The ABO blood-group differences
between the patient and the male partner
have an influence on the incidence of these
tumours and the ultimate prognosis. While
differences at the major histocompatibility
complex (HLA) do not affect the chance of a
woman getting a trophoblastic tumour,
patients producing HLA antibodies against
the male partner's antigens have a worse
prognosis than those who do not. Genetically,
these tumours arise in different ways: either
from normal zygotes with a maternal and a
paternal haplotype (normal pregnancy), or
from a triploid zygote (partial mole), or from
an XX zygote possessing only a duplicated
male haplotype and no maternal contribution
(complete mole). Further analysis of the
genetics ofthese tumours may well contribute
to an understanding of the process of
carcinogenesis.
Dr A. Szulman (U.S.A.) discussed the
differences between complete and partial
moles. In the classical hydatidiform mole,
there is the gross hydropic swelling of the villi
with a variable degree of trophoblastic
hyperplasia. These complete moles are
genetically XX, and are androgenetically
derived. The partial moles have less and
variable hydropic change in the villi, some of
wrhich retain vascularity and foetal red cells,
indicating that at some stage there had been
a coexisting foetus.
Mr M. Stone (London) presented the
evidence of a relationship between oral con-
traception and the proportion of patients
who require treatment following evacuation
of a hydatidiform mole. In a series of 611
consecutive patients who were followed-up
after a hydatidiform mole, 61 (10%) required
chemotherapy. In patients receiving an
oestrogen/progesterone preparation before
the HCG/LH valuesreached thenormal range,
the incidence requiring chemotherapy was
2-6 times greater than in those patients not
taking these preparations (the difference was
statistically significant). The oestrogen/pro-
gesterone preparation caused a delay in the
fall ofthe HCG concentration, even where the
mole eventually died out spontaneously. By
the third month after the evacuation of the
mole, the proportion of patients still ex-
creting abnormal concentrations of HCG was
405% in patients receiving oestrogen/pro-
gesterone preparations, compared with 18.4%
in those not receiving these preparations. At
present it is recommended that patients who
have had a hydatidiform mole should not be
put on any form of hormone contraception
until their HCG values have been normal for
3 months or more.
IMMUNOLOGY, ENDOCRINOLOGY AND ASSAYS
Three papers were presented on the role
of the pregnancy-specific /3, glycoprotein
(PSBG). Professor Yu. S. Tatarinov
(U.S.S.R.) presented his results with a radio-
immunoassay for PSBG. In this series all 15
hydatidiform moles had had elevated levels
of PSBG, whilst in a group of post-molar
trophoblastic tumours, 21/28 (75%) had
raised PSBG. In those with choriocarcinoma,
32/48 (67%) had raised PSBG. Of 197
patients with non-gestational trophoblastic
tumours, raised PSBG was found in 15.5% of
testicular tumours, and 12.5% of lung
tumours. The incidence of raised PSBG in
other tumours was low. Raised levels of
PSBG had a close correlation with the pre-
sence oftrophoblastic tumours and this could
be used both as a diagnostic test and in
monitoring patients with these tumours.
Dr F. Searle (London) presented some of
the results with an assay for PSBG at
Charing Cross Hospital. In the majority of
patients with choriocarcinoma, the concen-
trations of :-human chorionic gonadotrophin
(g-HCG) and PSBG show good correlation.
There is a sub-set of patients in whom the
PSBG remains high for substantial periods
after the 3-HCG has returned to normal, but
the significance of this remains uncertain. It
had been noted that in some patients, the
PSBG concentrations apparently rose at the
time of administration of certain cytotoxic
drugs, and this might relate to the release of
intracellular PSBG during these courses of
treatment.
Dr M. Seppala (Finland) presented results
in 17 patients with choriocarcinoma, 8 with
hydatidiform mole and 85 normal controls.
In patients with trophoblastic tumours and
raised HCG, the PSBG was also raised in
63%/. PSBG was also found in some patients
with choriocarcinoma whose HCG values had
become normal after treatment. 4.7% of the
controls were also found to have high PSBG
levels. PSBG measurements were thought to
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be an adjunct to HCG estimations in the
management of patients with trophoblastic
tumours.
Mr A. Kardana (London) discussed the
current development at Charing Cross Hos-
pital of an automated radioimmunoassay
machine for measuring various antigens. This
machine is capable of handling 5 different
assays at different stages concurrently. At
present, input dilution is the rate-limiting
step, and up to 300 reactions are possible per
hour. The application ofthis type of machine
to increasing the facilities for patient monitor-
ing for tumour markers was discussed.
Professor S. S. Ratnam (Singapore) pre-
sented results on steroidogenesis in patients
with hydatidiform moles. Maternal levels of
progesterone, oestradiol 17fl and testo-
sterone were significantly raised in these
patients, compared with normal pregnancy.
Molar vesicular fluid was found to contain
large amounts of progesterone and testo-
sterone. In vitro work showed conversion of
precursors to testosterone by molar tropho-
blast. The evidence suggested that molar
trophoblast is more active at steroidogenesis
than normal-pregnancy trophoblast.
Professor G. Crepin (France) presented the
results ofthyroid function in 17 patients with
hydatidiform mole. Six ofthese patients were
clinically hyperthyroid and this was con-
firmed biochemically. A further 6 patients
were found to have abnormal thyroid func-
tion when measured by radioimmunoassay
for the subunit ofhuman thyroid-stimulating
hormone and for responses to thyroid-releas-
ing hormone administration. The thyroid
stimulator was thought to be of placental
origin, and work is continuing to analyse
whether the thyroid stimulation is due to
HCG or to the production of a specific thyro-
tropin.
Dr M. Wass (London) presented evidence
that normal human serum contains anti-
bodies to human chorionic gonadotrophin/
luteinizing hormone (HCG/LH). Affinity
chromatography and specificity tests by
binding to iodinated HCG demonstrated that
the antibodies were predominantly of the
IgG class. A radioimmunaossay ofthese anti-
HCG/LH antibodies showed a wide range of
concentrations in sera from normal controls
and patients with various cancers.
Dr J. Arends (Denmark) reviewed the
current evidence about serum concentrations
of free HCG subunits in patients with gesta-
tional trophoblastic tumours. There is con-
flicting evidence in the literature about the
presence of free a-subunits in patients with
these tumours. It would appear that the con-
centrations ofthese a-subunits is low, and one
ofthe main problems is finding an assay with
sufficient specificity to detect low concentra-
tions of a-subunits in the presence of high
concentrations of whole HCG.
Miss J. Dent (London) presented the results
of the U.K. Hydatidiform Mole Follow-Up
Scheme. This started in January 1973 and
patients are registered at 3 Centres (London,
Sheffield and Dundee). Between 1973 and
1978 a total of 3,623 moles were registered at
these Centres. Many of those requiring treat-
ment were treated at Charing Cross and,
during this period, 236 patients were ad-
mitted for chemotherapy. Most of the follow-
up is done on urine samples, but normal
values are now confirmed with serum samples
for f-HCG. Patients with a hydatidiform
mole are followed-up for 2 years and further
samples are requested 3 weeks after any
future pregnancy, to exclude the presence ofa
further trophoblastic tumour.
Dr G. Bolis (Italy) presented the follow-up
of 172 patients with hydatidiform mole in
Milan. Only 7.5% of these required chemo-
therapy. In the patients who went into spon-
taneousremission, only8% ofthem continued
to have raised f-HCG concentrations more
than 12 weeks after evacuation of the mole.
A total of 70 pregnancies occurred in this
group, with 53% full-term deliveries, 4%
premature deliveries, 17% abortions and 4%
repeat hydatidiform mole.
Dr P. Walden (London) presented the
long-term follow-up of the obstetric history
of 314 patients who had been successfully
treated for trophoblastic tumours between
1962 and 1977. 159 of these patients subse-
quently completed 201 pregnancies. There
were 78% term births, 3% premature births,
12% abortions, 3% stillbirths and 4%
terminations. There were 7 infants with
foetal abnormalities, including 2 anencephalic
stillbirths. At present there is no clear indica-
tion that prior chemotherapy has an adverse
influence on subsequent pregnancies.
PROGNOSTIC FACTORS OF TROPHOBLASTIC
TUMOURS
Dr D. P. Goldstein (U.S.A.) presented a
therapeutic classification for gestational
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trophoblastic tumours based on 1300 patients
treated in Boston. After extensive pre-treat-
ment investigation to identify the extent of
the disease, patients are put in one of 5
Groups. Group 1, unevacuated molar preg-
nancy; Group 2 low-risk non-metastatic
disease; Group 3, high-risk non-metastatic
disease; Group 4, low-risk metastatic disease;
Group 5, high-risk metastatic disease. When
treatment is chosen appropriately for each
patient group remission rates are 100% for
Groups 1-4, and 80% in Group 5.
Professor K. D. Bagshawe (London) dis-
cussed the potential for drug resistance.
During the 1960s it was found that many
patients could be cured with methotrexate
(MTX) and folinic acid, with minimal
toxicity. However a proportion of patients
became resistant to MTX. An analysis of 317
patients identified a number of risk factors,
including: age, number of prior pregnancies,
type of pregnancy antecedent to the tumour,
interval from antecedent pregnancy to treat-
ment, amount of active trophoblast (as
indicated by HCG concentration) extent of
disease and sites of metastases, patient and
partner's blood groups, immune status and
prior chemotherapy. These risk factors appear
to interact and can be added together to give
an overall ranking for each patient. Patients
are classified into low, medium and high-risk
groups, and since 1974, treatment has been
chosen on the basis of these three groups.
Dr R. H. J. Begent (London) presented the
results of 189 patients treated between 1974
and 1978 at the Charing Cross Hospital on the
basis of the prognostic factors described
above by Professor Bagshawe. Patients in the
low-risk group were treated initially with
MTX and folinic acid alone. Although some
of these 78 patients required treatment with
additional agents, none died from a tropho-
blastic tumour. In the medium-risk group of
67 patients, 6 drugs were used in a sequential
manner and only one patient has died from
choriocarcinoma. There were 44 patients in
the high-risk group who were treated with an
intensive multi-drug schedule. Six patients
are known to have died from choriocarcinoma
and 2 were lost to follow-up, while 3 remain
on treatment. The remaining 33 (75%) are in
remission and offtreatment. Treating patients
in the high-risk group very intensively from
the starthas produced an improvement in the
survival over the previous series.
Dr E. J. Aartsen (Holland) presented the
results with gestational choriocarcinoma in
the Netherlands since 1962. Although the
introduction of MTX halved the death rate
from choriocarcinoma since 1962, there has
not been a progressive fall in death from this
disease since 1970. The main causes of the
failures have been relying on the standard
pregnancy test rather than radioimmuno-
assay for monitoring patients' treatment; and
the treatment of patients with adverse prog-
nostic factors with MTX alone, which has
produced drug resistance. There was also a
group ofvery high-risk patients who account-
ed for many of the failures.
Dr F. B. Lammes (Holland) presented the
results of the Netherlands Co-operative
Group for Choriocarcinoma. Between 1971
and 1976 the Group considered 65 patients.
The majority of the patients were being
followed-up after a hydatidiform mole. At
present the Group are basing their policy and
treatment on the low, medium and high-risk
groups described by Professor Bagshawe.
THERAPY
Professor S. S. Ratnam (Singapore) re-
viewed 850 cases of gestational trophoblastic
tumours that have been treated over the last
20 years. While chemotherapy with precise
HCG monitoring remains the most important
means of treating choriocarcinoma, selected
patients will benefit from surgery. In par-
ticular, patients with large tumour masses
can get a better subsequent response to
chemotherapy after removal ofthe main part
ofthe tumour.
Mr -M. Stone (London) presented data
indicating that the mode of primary treat-
ment of hydatidiform mole is important in
determining the incidence of subsequent
chemotherapy. 61/611 consecutive hydatidi-
form-mole patients required chemotherapy
for persistent tumour. When analysed by the
method ofinitial evacuation ofthe mole after
medical induction, hysterotomy or hysterec-
tomy, chemotherapy was required in 19.8%
of patients. This compares with 6% in
patients who had curettage or suction
evacuation.
Dr D. P. Goldstein (U.S.A.) discussed the
use of MTX with citrovorum factor in 61
patients with gestational trophoblastic
tumours. MTX was used in a dose of4 mg/kg
and 6 mg/kg followed by citrovorum-factor
rescue. The remission rates in non-metastatic
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and metastatic gestational trophoblastic
tumours were 88 and 80% respectively. The
higher dose of MTX did not reduce the need
for subsequent treatment, but did increase
the toxicity. If the HCG concentration did
not fall by more than 1 log within 18 days, it
was likely that the patient would require
additional treatment.
Dr J. J. Fennelly (Ireland) discussed his
results in treating 106 patients with gesta-
tional trophoblastic tumours over the last 15
years. Of 69 patients with hydatidiform mole,
one died from septicaemia, while the other
68 are in complete remission. Of 21 patients
with persistent trophoblastic activity, the
majority resolved on MTX treatment,
although 7 required hysterectomy. Sixteen
patients were seen with choriocarcinoma, and
5 of these died. The deaths of all 5 were
preventable in that they were patients who
had had a hydatidiform mole and had not
been adequately followed-up.
Dr C. E. Nystrom (Sweden) discussed the
importance of distinguishing the treatment
between invasive moles and pure chorio-
carcinoma. In addition to serial assays of
HCG, he has also been monitoring serum
diamine-oxidase levels which he has found
useful in monitoring these patients. He has
treated the invasive moles with MTX, whilst
the patients with choriocarcinoma have re-
ceived a multi-drug regime including vin-
cristine, MTX, melphalan and actinomycin D.
Professor Ho-Kei Ma (Hong Kong) re-
viewed the results of 85 patients treated
between 1972 and 1978. The patients have
been divided into low and high-risk groups on
the basis of: (1) the interval between the
antecedent pregnancy and treatment; (2) the
HCG concentration; (3) the extent and sites
of tumour; (4) response to previous chemo-
therapy. Up to 1976 all pati6nts had initially
been treated with MTX alone. Since 1976 all
high-risk patients have been treated with
intensive combination chemotherapy with
hydroxyurea, vincristine, MTX, cyclophos-
phamide, actinomycin D and adriamycin.
The complete remission rate was 86%. One
low-risk and 7 high-risk patients have died.
In the high-risk patients, initial combination
chemotherapy has been more effective than
single drug therapy.
Dr W. Jones (U.S.A.) discussed the treat-
ment ofhigh-risk patients with trophoblastic
tumours. The high-risk patients had high
HCG concentrations (> 100,000 i.u./24 h) and
an interval from the antecedent pregnancy
>4 months. In the 30 high-risk patients
analysed, 90% of those without liver and
brain metastases went into complete re-
mission, whilst only 44% of patients with
liver and brain metastases went into re-
mission. The overall results in these high-risk
patients was a remission rate of 76%. The
present chemotherapy for these high-risk
patients is a combination of MTX, actino-
mycin D and chlorambucil.
Dr E. A. Surwit (U.S.A.) presented the
results of 51 patients presenting with adverse
prognostic factors between 1968 and 1978.
37/51 patients (72%) are in remission. Fac-
tors that were associated with a poor outcome
were: previous unsuccessful chemotherapy
(53% survival compared with 82% in those
receiving no prior treatment,) a longer inter-
val from the antecedent pregnancy, and
metastases of liver and brain. Since 1976
more aggressive initial chemotherapy has
achieved remission in 17/19 (90%) of high-
risk patients.
Dr E. S. Newlands (London) presented the
activity of 2 new drugs in treating drug-
resistant choriocarcinoma. The results at the
Charing Cross Hospital using the semi-
synthetic epipodophyllin derivative, VP 16-
213 (etoposide), have shown 12 improve-
ments and responses out of 18 patients. In
view ofthe mild toxicity with this agent, it is
very promising as an additional active agent
against trophoblastic tumours. Using high-
dose Cis-Platinum in combination with vin-
cristine and MTX has so far produced 13
improvements and responses in 16 patients.
However, in the 2 patients where Cis-
Platinum has been used alone, no responses
have been seen. Cis-Platinum may have a
role in treating high-risk patients when used
in combination with other agents.
REVIEW
Dr J. Lewis (U.S.A.) reviewed the develop-
ment ofchemotherapy for gestational tropho-
blastic tumours since the introduction of
MTX in 1955 at the National Institutes of
Health by Hertz and Li. With the addition
ofother agents such as actinomycin D, many
patients can be put into complete remission
with chemotherapy. However, recognition of
drug resistance, and problems in patients
with wide-spread disease, anticipated the
later ranking of patients into low, medium
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and high-risk groups. During the 1960s, the
development of radioimmunoassay for HCG
improved the monitoring of patients with
these tumours. Further reviews of the
National Institute of Health Series, which is
the earliest of the series of patients cured
with chemotherapy alone, havenotshownany
significant increase in birth abnormalities in
the 96 pregnancies that have occurred in 58
of the patients. Review of 175 patients in
1973 has so far only picked up one tumour
which could have been induced by the chemo-
therapy (a case ofHodgkin's Diseaseoccurring
31 years after chemotherapy).
Professor Bagshawe (London) reviewed
some of the points that had been raised in
discussion earlier in the meeting. At present,
the current recommendation for patients who
have had a hydatidiform mole is that their
HCG concentration should be normal for at
least 6 months before the patient has a
further pregnancy. Patients who have had a
mole should be followed up for 2 years, as
occasionally (one in 500 cases) therehas been a
recurrence after the HCG has fallen to the
normal range. The development of the
schedules using MTX and folinic acid have
resulted in a greater safety margin when the
patient receives folinic acid, than with MTX
alone. At present, there is no evidence that,
where a trophoblastic tumour is resistant to
low-dose MTX, increasing the dose produces a
better response. In the Charing Cross series,
where morethan90% ofthe500 patients have
beenfollowed-upforbetween 1 and20years, so
fartherehaveonlybeen 2 secondtumours (one
carcinoma ofthe cervix,andoneacutemyeloid
leukaemia). CNS involvement at the onset of
therapy is not necessarily disastrous. In a fair
proportion of patients, the tumour can be
eliminated even in this site with a combina-
tion of systemic therapy and intrathecal
MTX. High-dose systemic MTX (3 g/m2) can
produce what is probably a therapeutic con-
centration (> 10-6M) of MTX in the CSF at
the end of the 24h infusion. The role of this
approach in therapy has yet to be finalized.
Overall, there has been a progressive improve-
ment in the survival of the patients since the
introduction ofchemotherapy, and at present
the current survival rate in the Charing Cross
Series is 94%.
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